In patients with advanced hepatocellular carcinoma, TACE plus thymosin alpha‑1 gave a higher CD3+ T cell percentage than TACE alone at 1 week, 4 weeks and 3 months.
In plain wordsIn patients with advanced liver cancer, adding thymosin alpha‑1 to TACE gave higher CD3+ T cell levels than TACE alone.
- Peptide
- Thymosin alpha-1
- Outcome
- IncreaseCD3+ T cell percentage after TACE
- Study
n = 30
- Comparator
- TACE alone
- Outcome group
- Immune response · Immune and inflammation
- Studied dose
- 1.6 mg twice a week · subcutaneous injection · 4 weeksAs given in this study (human).
Source sentences
The percentage of CD3(+) , CD4(+) , CD8(+) T cell subsets in TACE+ Tα1 group
4 context sentences(design, population, supporting numbers)
were statistically higher than those in TACE group at 1 week post-TACE treatment (53.71%±11.17%, 32.12%±10.53%, 24.45%±13.72%) at 4 weeks post-TACE treatment (52.12%±14.26%, 31.16%±15.43%, 23.39%±15.33%) and 3 months follow-up (54.28%±13.15%, 32.17%±14.98%, 24.34%±14.12%) (P<0.05)
A total of 30 patients with advanced liver cancer enrolled in Lishui Central Hospital from September 2015 to June 2016 were collected in this study.
Patients were divided into TACE group and TACE+ Tα1 treatment group(15 cases in each group).
Patients in TACE group received a conventional treatment, without any immunotherapy, while the TACE+ Tα1 treatment group accepted TACE following a subcutaneously injection of 1.6 mg Tα1 twice a week for 4 weeks.